To date, several factors have been identified as influencing immunotherapy efficacy, such as PD-L1 expression, tumor mutational burden, effective T-cell infiltration, TGF-β activity, previous treatments and tumor proliferative potential (7). The gene discussed is TGFB1; the disease is neoplasm.